Z
Zai Lab Limited (ZLAB)
NGM – Real Time Price. Currency in USD
18.00
-0.52 (-2.81%)
At close: Jun 26, 2026, 4:00 PM EDT
17.90
-0.10 (-0.56%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NGM – Real Time Price. Currency in USD
18.00
-0.52 (-2.81%)
At close: Jun 26, 2026, 4:00 PM EDT
17.90
-0.10 (-0.56%)
After-hours: Jun 26, 2026, 7:56 PM EDT
Zai Lab Limited, a biopharmaceutical company, focuses on discovering, developing, and commercializing products that address medical conditions in the areas of oncology, immunology, neuroscience, and infectious diseases. Its commercial products include Zejula, an orally administered poly (ADP-ribose) polymerase 1/2 inhibitor for treating ovarian cancer; VYVGART, a human IgG1 antibody fragment for generalized myasthenia gravis and chronic inflammatory demyelinating polyneuropathy; NUZYRA for community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections; Optune for glioblastoma multiforme; Qinlock for gastrointestinal stromal tumors; Xacduro for treating hospital-acquired and ventilator-associated bacterial pneumonia caused by a cinetobacter baumannii-calcoaceticus complex; and Augtyro for the treatment of ROS proto-oncogene 1 and non-small cell lung cancer. The company has a strategic collaboration with Tesaro, Inc., NovoCure Ltd., Deciphera Pharmaceuticals, LLC, Paratek Bermuda Ltd., argent BV, Turning Point Therapeutics, Inc., Entasis Therapeutics Holdings Inc., Karuna Therapeutics, Inc., Pfizer Inc., Amgen Inc., and with Boehringer Ingelheim GmbH. The company was incorporated in 2013 and is based in Pudong, China.
| Name | Position |
|---|---|
| Dr. James Yan DABT, M.D., Ph.D. | Chief Operating Officer of Global R&D |
| Dr. Rafael G. Amado M.D. | President and Head of Global Research & Development |
| Dr. Shan He Ph.D. | Senior VP & Chief Business Officer |
| Dr. Yajing Chen Ph.D. | Chief Financial Officer |
| Dr. Ying Du Ph.D. | Founder, Chairperson & CEO |
| Mr. Frazor Titus Edmondson III, J.D. | Chief Legal Officer & Corporate Secretary |
| Ms. Christine Chiou | Senior VP & Head of Investor Relations |
| Date | Type | Document |
|---|---|---|
| 2026-06-17 | 8-K | zlab-20260617.htm |
| 2026-05-21 | 8-K | zlab-20260518.htm |
| 2026-05-07 | 8-K | zlab-20260507.htm |
| 2026-05-07 | 10-Q | zlab-20260331.htm |
| 2026-04-28 | DEFA14A | a2026defa14a.htm |
| 2026-04-28 | DEF 14A | zlab-20260428.htm |
| 2026-04-28 | ARS | a2025-12x31xfilingx2026x04.pdf |
| 2026-04-17 | PRE 14A | zlab-20260417.htm |
| 2026-02-26 | 8-K | zlab-20260226.htm |
| 2026-02-26 | 10-K | zlab-20251231.htm |